Related Experiment Video

Updated: May 15, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity

Christophe Rochais1, Thierry Cresteil, Vittoria Perri

  • 1CERMN, UFR des Sciences Pharmaceutiques, UPRES EA 4258 - FR CNRS 3038 INC3M - SF 4206 ICORE, Université de Caen Basse-Normandie, Bd Becquerel, 14032 Caen cedex, France. christophe.rochais@unicaen.fr

Cancer Letters
|December 27, 2012
PubMed

Insights

A new anti-cancer drug, MR22388, shows high effectiveness against various cancer cells. It targets specific mutated kinases, offering promise for treating Acute Myeloid Leukemia (AML).

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Acute Myeloid Leukemia (AML) with FLT3-ITD mutations has a poor prognosis.
  • Targeting mutated tyrosine kinases is a key strategy in cancer therapy.

Purpose of the Study:

  • To investigate the mechanism of action and activity spectrum of the novel anti-cancer agent MR22388.
  • To evaluate MR22388's potential as a therapeutic agent, particularly for AML.

Main Methods:

  • Cytotoxicity assays against various cancer cell lines.
  • Analysis of tubulin polymerization inhibition.
  • Investigation of apoptosis induction via MAP kinase pathways.
  • Kinase inhibition assays, focusing on FLT3-ITD.

Main Results:

  • MR22388 exhibits high cytotoxicity in the nanomolar range against multiple cancer cell lines.
  • It weakly inhibits tubulin polymerization but effectively induces apoptosis through MAP kinase pathways.
  • MR22388 strongly inhibits key kinases, including the mutated FLT3-ITD tyrosine kinase.

Conclusions:

  • MR22388 demonstrates a promising anti-cancer profile, with potent activity against cancer cell lines.
  • Its mechanism involves apoptosis induction and strong inhibition of critical kinases like FLT3-ITD.
  • MR22388 represents a potential novel therapeutic lead for AML treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...